Dina Fine Maron, Editor of Health & Medicine at Scientific American, joins Cheddar to discuss some of the biggest changes to science regulations we'll see in 2018. From food labels to nonaddictive cigarettes, people need to be aware of what might affect their everyday lives.
A revamped nutrition label was slated to debut in July of 2018, however the Trump administration is giving companies a longer window. Major companies now have until 2020 and smaller companies have until 2021. The new labels will have more detail on added sugar and calorie count. However, critics say the delay could be a major blow to the public's health.
Plus, the U.S. Food and Drug Administration aims to create a nonaddictive cigarette with lower nicotine levels. It hopes this will help smokers quit. However, the agency opened up the conversation to the public for input which will ellicit some strong views from the tobacco industry.
The sophisticated rocket sent a payload that included 24 satellites, a new, solar-powered space sail, and the ashes of 152 people, into space with its side boosters successfully returning to Earth unscathed.
That next step for meat alternatives will apparently include fish as companies like Wild Type, BlueNalu, and Finless Foods wager that, in the age of plant-based burgers, there’s room for seafood grown in the lab.
These are the headlines you Need 2 Know for Wednesday, June 19, 2019.
Elon Musk may be going to Vegas. The Las Vegas Convention and Visitors Authority has recommended that The Boring Company be chosen to construct a "people mover" below the expanding convention center.
Cannabis, hemp, reefer, marijuana, dope, pot, grass ー no matter what term you choose, they all refer to the same plant: cannabis sativa. It’s a common misconception that cannabis sativa exclusively means that particular strain of weed that makes you creative and focused (as opposed to indica, which promotes relaxation)ー but it’s actually the scientific name of the single plant that yields marijuana, CBD, and hemp, among other products.
These are the headlines you Need 2 Know for Tuesday, Feb. 19, 2019.
Canopy Growth CEO Bruce Linton won't guarantee investors dividends. What he will promise is a stake in global cannabis domination. "If people want a dividend, we are probably not the right stock. If they want some entity aimed at dominating a global opportunity that started in Canada, we are probably your best bet," Linton told Cheddar on Friday, one day after the company reported a massive spike in third-quarter revenue.
These are the headlines you Need 2 Know for Friday, Feb, 15, 2019.
It's a big week in cannabis earnings ー Aurora Cannabis reported Monday and Canopy Growth will report Thursday ー but Paul Rosen, CEO of cannabis private equity firm Tidal Royalty, said he's noticing a concerning trend."All the companies are facing gross margin compression because there are excise taxes, there's a massive marketing spend as we go to recreational cannabis, and there's also increased packaging costs. So I think you're going to see a trend line here, which is revenue and capacity going up, but gross margin is going down," Rosen told Cheddar Wednesday.
Opiant Pharmaceuticals, the developer of opioid antidote NARCAN, is in the process of developing a version of its lifesaving drug for cannabanoid overdoses, the company's CEO told Cheddar in an interview on Wednesday.
